
We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.
✓
We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.

⭐ We spoke with Sabina Signoretti, MD, of @harvardmed, on her team’s analysis of the phase 2 HCRN GU16-260 trial examining biomarkers of response to frontline nivolumab in metastatic clear-cell #RCC: buff.ly/bdGKDd3 🔎 The study drew on multiplex immunofluorescence and spatial profiling of the tumor microenvironment, and identified immune cell populations associated with favorable and unfavorable outcomes.

Many congratulations Berkay Simsek for being a recipient of the KCRS 2025 Merit Awards for Translational Research @simsek_berkay_ @kidneycan @MassGenBrigham #KCRS25 #kidneycancer

The #KCRS2025 @kidneycan is also about ART!

#KCRS25 Oral Abstract: @simsek_berkay_ @BrighamWomens links CD163+ macrophages in RCC tumors to better outcomes with nivolumab. A potential new target for immunotherapy. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

Pathologist representation at this year’s #KCRS25, one of my most important and favorite meetings each year. 🔬🩺🩻 #gupathology #workingtogethertofightRCC @PayalKapur5 @Unclassified1 @drmehrarohit @kidneycan @OncoAlert @urotoday

So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan

Thanks to our friends at Cure Today for letting me share some advice for new patients. 👊👊 @DanaFarber @DrChoueiri @DanaFarber_GU @kidneycan @TheJimmyFund @DanaFarberNews curetoday.com/view/finding-s…

Celebrating Dr Sabina Signoretti @BrighamWomens work and dedication over the years to @DanaFarber @BrighamWomens @df_hcc Pathology! cc: @LabSignoretti @kaelin_lab @harvardmed

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.

Sarcomatoid RCC #kidneycancer : Diagnostic Updates and Therapeutic Implications. Comprehensive talk by @SabinaSign16728 @BrighamWomens 👉epigenomics, genetics and inflammed phenotype of Sarcomatoid RCC & Rx implications #KCRS24 @kidneycan @DrChoueiri @TalalZarif1 @OncoAlert

Kicking off the Trials in Progress session with #ARCITECT evaluating Botensilimab+Balstilimab for pts with mRCC A trial that aims to "raise the tail" and a fantastic presentation by @MikeSerzanMD #KCRS24 @kidneycan @OncoAlert


The #INTerpath-004 trial explores the combination of pembro + personalized mRNA #vaccine for the adjuvant treatment of pts with RCC. Inspiring talk by @DrChoueiri at #KCRS24! @kidneycan @DanaFarber_GU @OncLive

🟢 Outstanding presentation at #KCRS24 @drmehrarohit 🟠 Role of Pathologist in Kidney Cancer Diagnostics and Research 🟠 Highlighting the morphologic diversity in renal tumors and its diagnostic implications. 🟠 Emphasis on understanding mechanisms to improve patient care. @KidneyCancer @DrChoueiri @yekeduz_emre @neerajaiims @montypal @NazliDizman @advocatekidneys @HHammersMD @rovingatuscap @BraunMDPhD @DrRanaMcKay @FabioSchutz78 @AlbigesL @OncoAlert #cancer #oncology #KidneyCancer #KCRS24

We are super interested in the IVC thrombus @UTSWUrology @utswcancer @UTSWHemeOnc! @PayalKapur5 shows IVC correlates and Angioscore for as a biomarker for angiogenic driven tumor. @KCPUTSW #KCRS24 @kidneycan